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Background: Latrepirdine is an orally administered ex-
perimental small molecule that was initially developed
as an antihistamine and subsequently was shown to sta-
bilize mitochondrial membranes and function, which
might be impaired in Huntington disease.
Objective: To determine the effect of latrepirdine on
cognition and global function in patients with mild to
moderate Huntington disease.
Design: Randomized, double-blind, placebo-
controlled study.
Setting: Sixty-four research centers in Australia, Eu-
rope, and North America.
Patients:Four hundred three patients withmild tomod-
erate Huntington disease and baseline cognitive impair-
ment (Mini-Mental State Examination score, 10-26).
Intervention: Latrepirdine (20 mg) vs matching pla-
cebo administered orally 3 times daily for 26 weeks.
Main Outcome Measures: The co-primary outcome
measures were cognition as measured by the change in
Mini-Mental State Examination score from baseline to
week 26 and global function at week 26 as measured by
theClinician Interview–Based Impression ofChange, plus
carer interview, which ranges from 1 (marked improve-
ment) to 7 (marked worsening). Secondary efficacy out-
come measures included behavior, daily function, mo-
tor function, and safety.
Results: Themean change inMini-Mental State Exami-
nation score among participants randomized to latrepir-
dine (1.5-point improvement) did not differ signifi-
cantly from that among participants randomized to
placebo (1.3-point improvement) (P=.39). Similarly, the
distribution of the Clinician Interview–Based Impres-
sion of Change, plus carer interview did not differ sig-
nificantly among those randomized to latrepirdine com-
pared with placebo (P=.84). No significant treatment
effects were detected on the secondary efficacy outcome
measures. The incidence of adverse events was similar
between those randomized to latrepirdine (68.5%) and
placebo (68.0%).
Conclusion: In patients with mild to moderate Hun-
tington disease and cognitive impairment, treatmentwith
latrepirdine for 6months was safe and well tolerated but
did not improve cognition or global function relative to
placebo.
Trial Registration: clinicaltrials.gov Identifier:
NCT00920946
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H UNTINGTONDISEASE (HD)is an autosomal domi-nant neurodegenerativedisorder that is charac-terized by involuntary
movements, behavioral disorders, and cog-
nitive dysfunction. The symptoms typi-
cally begin in the fourth decade of life and
lead to progressive deterioration in func-
tional capacity and independence.1 Cur-
rent treatment is symptomatic, but no
treatments are available for the cognitive
dysfunction in HD.2
Latrepirdine is an orally administered
experimental small molecule that was ini-
tially developed as an antihistamine and
subsequently was shown to stabilize mi-
tochondrial membranes and function,2-5
whichmight be impaired inHD.6,7 In a pre-
vious randomized trial8 of latrepirdine in
91 individuals withmild tomoderate HD,
latrepirdine was found to be safe and well
tolerated during 90 days of treatment. In
addition, comparedwith placebo, latrepir-
dine treatmentwas associatedwith amean
0.97-point improvement in the Mini-
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Mental State Examination (MMSE) score but not with
improvement in other cognitive outcomemeasures. Based
on the results of this phase 2 study, we conducted an in-
ternational, multicenter, randomized, double-blind, pla-
cebo-controlled study of latrepirdine to assess its effi-
cacy in improving cognition and global function in
patients with mild to moderate HD.
METHODS
STUDY ORGANIZATION AND DESIGN
The multicenter clinical trial was organized and conducted by
the Huntington Study Group and the European Huntington’s
Disease Network.
We conducted a randomized, double-blind, placebo-
controlled, parallel-group trial of latrepirdine (20mg) vsmatch-
ing placebo administered orally 3 times daily for 26 weeks. The
protocol and consent forms were approved by the University
of Rochester (Rochester, New York) institutional review board
and by the institutional review board at each participating site.
Eligible study participants provided written consent. After
eligibility for the study was confirmed, participants were ran-
domized in a 1:1 ratio to latrepirdine or placebo according to a
computer-generated permuted block randomization schedule
that was stratified by site and by concomitant use of tetrabena-
zine. Blinded treatment assignment was provided by an inde-
pendent interactive web and voice recognition service. Indi-
viduals randomized to latrepirdine received latrepirdine (10mg)
3 times daily for the first 7 days, followed by latrepirdine (20
mg) 3 times daily for the remainder of the treatment period.
Participants, investigators, and sponsors weremasked to study
group assignment.
After a screening visit to determine eligibility, a baseline visit
was conducted within 32 days of screening, followed by in-
person visits at weeks 2, 6, 13, 18, and 26 after baseline. A tele-
phone safety assessment was performed 4 to 8 days after the
baseline visit, and a follow-up visit was conducted at week 30
(4 weeks after the last administration of study drug) to assess
safety in participants who did not choose to enroll in an open-
label extension study of latrepirdine immediately following the
week 26 visit.
STUDY PARTICIPANTS
Study participants were recruited from 64 research centers in
Australia (n=3), Europe (n=28), and North America (n=33).
Eligible participants were at least 30 years old, had clinical fea-
tures of mild to moderate HD based on a Unified Huntington’s
Disease Rating Scale9 total functional capacity of 5 to 13, and
had a trinucleotide (cytosine-adenine-guanine) repeat length
of 36 or greater in the huntingtin gene by direct DNA test-
ing.10 Participants had to have subjective evidence of cogni-
tive impairment as assessed by the site investigator and anMMSE
score of 10 to 26 at both the screening and baseline visits (be-
fore study drug administration). Participants were ambula-
tory, did not require skilled nursing care at baseline, and agreed
to use adequate birth control or were not of reproductive po-
tential. Individuals taking antidepressants, neuroleptics, or tet-
rabenazine had to be receiving stable dosages before random-
ization. All the participants had to have a caregiver who assisted
or spent time with the individual at least 5 days per week for
at least 3 hours per day and who was willing to provide input
on outcome measures.
Excluded from the study were individuals who had active
suicidal ideation or any major medical illness that would in-
terfere with their ability to complete the study procedures, in-
cluding diabetes mellitus requiring treatment with insulin or
a history of cancerwithin 5 years (excluding stable prostate can-
cer or nonmelanoma skin cancer). Individuals with active car-
diovascular disease, bradycardia (heart rate, !45 beats/min),
significant electrocardiographic abnormalities, hypotension (sys-
tolic blood pressure,!86 mmHg), or uncontrolled hyperten-
sion (successive blood pressures,"170/105mmHg) were also
excluded. Additional exclusionary criteria were significant labo-
ratory abnormalities, significant use of narcotic analgesics, a
history of human immunodeficiency virus, a history of sei-
zures requiring ongoing treatment, a history of other diseases
known to affect cognition (eg, significant traumatic brain in-
jury or dementing illnesses other than HD), and recent use of
clozapine, memantine hydrochloride, bupropion hydrochlo-
ride, a cholinesterase inhibitor, or a nonselective antihista-
mine.
OUTCOME MEASURES
The study had 2 co-primary outcome measures. The first was
the change from baseline to week 26 in cognition as measured
by the MMSE.11,12 The second was the change in global func-
tion at week 26 as measured by the Clinician Interview–Based
Impression of Change, plus carer interview (CIBIC-Plus).13 The
MMSE score was selected as a co-primary outcomemeasure be-
cause of its frequent use in dementia trials,14-16 its gradual de-
cline in HD,17 and its signal of benefit in previous trials involv-
ing latrepirdine.8,18 The CIBIC-Plus, which is widely used in
dementia trials,13 was used as a co-primary outcome measure
to provide a global assessment of function and to support the
clinical relevance of a treatment effect on theMMSE score. The
CIBIC-Plus comprises Likert-type scales for disease severity and
change from baseline based on semistructured interviews of the
research participant and the caregiver.19 The site investigator
conducted the MMSE at the screening, at baseline, and at vis-
its at weeks 6, 13, and 26. A separate, independent rater, blinded
to other aspects of the study, conducted the semistructured in-
terviews at baseline, at week 13, and at week 26. Secondary ef-
ficacy outcomemeasures included changes frombaseline toweek
26 in behavior as measured by the Neuropsychiatric Inven-
tory,19-21 activities of daily living as measured by the Alzhei-
mer’s Disease Cooperative Study–Activities of Daily Living
Scale,22 and motor function as measured by the Unified Hun-
tington’s Disease Rating Scale total motor score.9
Safety was addressed at all the study visits and included as-
sessment of adverse events, evaluation of suicidality using the
ColumbiaClassificationAlgorithmof Suicide Assessment,23 and
review of vital signs, electrocardiographic reading, concomi-
tant medication use, and laboratory test results, including se-
rum chemistry levels, hematology, and urinalysis. The safety
of participants was gauged by a clinical monitor from the spon-
sor, by the Huntington Study Group, and by an independent
data monitoring committee that reviewed safety data and had
access to treatment assignments.
STATISTICAL ANALYSIS
The primary statistical analyses were performed in accord with
a modified version of the intent-to-treat principle. For each of
the co-primary outcomemeasures, participantswhodid not have
at least 1 postbaseline value were excluded from the analysis
of that outcome variable. The change inMMSE score from base-
line to week 26 was analyzed using a mixed-model repeated-
measures approach.24 As independent variables, the model in-
cluded treatment group, baseline MMSE score, tetrabenazine
use (yes or no), region (Australia or North America vs Eu-
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rope), and week (6, 13, and 26, treated as a categorical vari-
able), as well as the interaction between treatment group and
week. The covariance matrix for the within-subject measure-
ments was specified as unstructured for model fitting. This ap-
proach appropriately accounts for missing data when estimat-
ing the model parameters under the “missing at random”
assumption.25 The treatment effect at week 26 (difference in
adjusted mean response between the latrepirdine and placebo
groups), with corresponding 95% CI and P value, was esti-
mated using this model.
For the CIBIC-Plus at week 26, the distribution of re-
sponses was compared between the latrepirdine and placebo
groups using a stratified Cochran-Mantel-Haenszel mean score
test26 using equally spaced scores for the categories of marked
improvement, moderate improvement, minimal improve-
ment, no change, minimal worsening, moderate worsening,
and marked worsening, along with stratification factors that
included tetrabenazine use and the baseline Clinician Inter-
view–Based Impression of Severity score, categorized as 1 to 3
(normal to mildly ill), 4 (moderately ill), or 5 to 7 (markedly
ill to extremely ill). For the analyses of the CIBIC-Plus, miss-
ing values were imputed by carrying forward the last available
postbaseline observation. For a beneficial effect of latrepir-
dine to be declared, the treatment effects on both the change
in MMSE score and the CIBIC-Plus at week 26 were required
to be statistically significant at the 5% level (2-tailed) in favor
of latrepirdine.
The mixed-model repeated-measures analyses were ap-
plied to secondary efficacy outcomes, as well as changes from
baseline in continuous safety outcomes (vital signs, labora-
tory test results, and electrocardiographic reading). Adverse
events were summarized as the percentage of participants in
each treatment group who experienced the event at least once
during the trial.
The intended sample size for the study was 350 study par-
ticipants (175 per treatment group). Assuming an SD of 3.2
for the change in MMSE score, an SD of 1.2 for the
CIBIC-Plus, and a 10% dropout rate, this sample size pro-
vided approximately 99% power to detect a 1.6-point differ-
ence in the mean response between the latrepirdine and pla-
cebo groups on the MMSE and approximately 84% power to
detect a 0.4-point difference in the mean response on the
CIBIC-Plus using a 5% significance level (2-tailed). There-
fore, the overall power to detect treatment effects on both out-
come variables was at least 83%, assuming a nonnegative cor-
relation between these variables.
RESULTS
STUDY PARTICIPANTS
From July 9, 2009, to July 10, 2010, a total of 519 indi-
viduals were screened, and 403 participants were ran-
domized to the study arms (Figure 1). Failing to meet
inclusion criteria (n=56) was the most common reason
for exclusion, with another 52 individuals failing tomeet
MMSE enrollment criteria. Data from 396 of 403 partici-
pants (98.3%) were included in the primary analyses of
the MMSE; 7 participants did not have a postbaseline
MMSE evaluation. Data from 393 of 403 participants
(97.5%) were included in the primary analyses of the
CIBIC-Plus; 10 participants did not have a postbaseline
CIBIC-Plus evaluation.Data fromall 403participantswere
included in the safety analyses. The baseline demo-
graphic and clinical characteristics of the study partici-
pants randomized to latrepirdine (n=200) and placebo
(n=203) were similar (Table 1).
EFFICACY
The mean change in the MMSE score from baseline to
week 26 was not significantly different for those ran-
domized to latrepirdine (1.5-point improvement) com-
pared with those randomized to placebo (1.3-point im-
provement) (P = .39) (Table2). In both groups, themean
MMSE scores significantly improved from baseline dur-
ing the course of the study (Figure 2), but no signifi-
cant difference between groups was observed at any time
point. Exploratory analyses found that the effect of
latrepirdine did not depend on age, sex, years of educa-
tion, tetrabenazine use, region, or baselineMMSE score.
Similarly, the distribution of the CIBIC-Plus did not dif-
fer significantly between the groups at week 26 (P = .84),
with most participants demonstrating minimal change,
if any, during the treatment period (Table 3). No sig-
nificant differences between groups were observed in the
secondary efficacy outcome measures assessing behav-
ior, motor function, or activities of daily living (Table 2).
Medication compliance, as measured by the percentage
of study medication that was taken on schedule, was on
average greater than 95% in both treatment groups.
SAFETY
Latrepirdine was well tolerated in the study, with 93.5%
of research participants randomized to latrepirdine com-
pleting the 6-month study compared with 91.6% of re-
searchparticipants randomized toplacebo (Figure 1).Dur-
ing the study, 10%of those receiving latrepirdine had their
study medication temporarily suspended because of an
Assessed for eligibility519
Enrollment
Allocation
Excluded100
Did not meet other inclusion criteria56
Exclusionary medication12
Abnormal safety tabs10
Other medical, psychiatric, or
surgical conflicts
9
Other13
Declined16
Allocated to latrepirdine200
Received allocated
intervention
200
Allocated to placebo203
Received allocated
intervention
203
Analysis
of primary
outcomes
Included in the analysis
of MMSE
196
Excluded from the 
analysis
4
Excluded from the 
analysis
5
Included in the analysis
of CIBIC-Plus
195
Included in the analysis
of MMSE
200
Excluded from the 
analysis
3
Excluded from the 
analysis
5
Included in the analysis
of CIBIC-Plus
198
403 Randomized
Figure 1. Participant flow. CIBIC-Plus indicates Clinician Interview–Based
Impression of Change, plus carer interview; MMSE, Mini-Mental State
Examination.
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adverse event compared with 5% of those receiving pla-
cebo.
In the clinical trial, 21 participants (9 randomized to
latrepirdine and 12 randomized to placebo) experi-
enced a serious adverse event. One death occurred dur-
ing the study in a 56-year-old woman who was random-
ized to latrepirdine and had respiratory arrest from a
presumed aspiration event that was assessed as unre-
lated to the study drug. Overall, 68.5% of those random-
ized to latrepirdine and 68.0% of those randomized to
placebo experienced an adverse event. The most com-
mon adverse events in the study were falls, worsening
chorea, and somnolence (Table4). Only fatigue and dry
mouth occurred more frequently in latrepirdine-treated
participants than in placebo-treated participants. Three
events indicating suicidality (suicide attempt, parasui-
cide gesture, and suicidal ideation), all in individuals ran-
domized to placebo, occurred during the study. After base-
line, 11 individuals randomized to placebo (5.4%)
reported suicidality, and 3 individuals randomized to
latrepirdine (1.5%) reported suicidality (P = .03) accord-
ing to the Columbia Classification Algorithm of Suicide
Table 1. Baseline Demographic and Clinical Characteristics of the Study Participants
Characteristic
Latrepirdine Group
(n = 200)
Placebo Group
(n = 203)
Age, mean (SD), y 53.3 (9.7) 51.6 (10.2)
Female sex, No. (%) 110 (55.0) 100 (49.3)
Race/ethnicity, No. (%)
White 195 (97.5) 193 (95.1)
Black 2 (1.0) 4 (2.0)
Other 1 (0.5) 4 (2.0)
Not reported 2 (1.0) 2 (1.0)
Education, mean (SD), y 13.1 (3.1) 13.1 (3.0)
Region, No. (%)
North America 71 (35.5) 73 (36.0)
Europe 121 (60.5) 123 (60.6)
Australia 8 (4.0) 7 (3.4)
Time since diagnosis, mean (SD), y 4.4 (3.6) 4.4 (3.5)
Tetrabenazine use, No. (%) 32 (16.0) 31 (15.3)
Baseline MMSE score, mean (SD) 22.6 (3.0) 22.2 (2.8)
Clinician Interview–Based Impression of Severity, No. (%)
Normal 0 0
Borderline ill 6 (3.0) 5 (2.5)
Mildly ill 51 (25.5) 56 (27.6)
Moderately ill 97 (48.5) 96 (47.3)
Markedly ill 38 (19.0) 35 (17.2)
Severely ill 8 (4.0) 11 (5.4)
Extremely ill 0 0
Neuropsychiatric Inventory total score, mean (SD) 9.3 (9.9) 8.4 (8.6)
Alzheimer’s Disease Cooperative Study–Activities of Daily
Living Scale total score, mean (SD)
59.6 (14.1) 59.3 (14.4)
Unified Huntington’s Disease Rating Scale, mean (SD)
Total functional capacity 7.5 (2.1) 7.6 (2.0)
Total motor score 41.9 (16.1) 42.0 (17.0)
Abbreviation: MMSE, Mini-Mental State Examination.
Table 2. Treatment Effects on Efficacy Outcomes at Week 26a
Outcome Variable
Mean Change
Treatment Effect (95% CI) P ValueLatrepirdine Group
Placebo
Group
Co-primary outcome measure
MMSE score 1.5 1.3 0.2 (−0.3 to 0.7) .39
Secondary efficacy outcome measures
Neuropsychiatric Inventory total score −1.6 −1.7 0.2 (−1.2 to 1.6) .82
Alzheimer’s Disease Cooperative Study–Activities
of Daily Living Scale total score
−1.8 −0.8 −0.9 (−2.6 to 0.8) .28
Unified Huntington’s Disease Rating Scale total motor
score
1.8 1.5 0.3 (−1.4 to 2.1) .72
Abbreviation: MMSE, Mini-Mental State Examination.
aThe mean changes and treatment effects are estimated using a repeated-measures analysis of covariance model with week, region, treatment group, baseline
MMSE score, tetrabenazine use, and the interaction between week and treatment group. See the “Statistical Analysis” subsection for details.
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Assessment. No significant group differences in vital signs
were found except for weight gain in those randomized
to latrepirdine (0.97 vs 0.04 kg in those randomized to
placebo; treatment effect, 0.94 kg; 95% CI, 0.22-1.65;
P = .01).
COMMENT
In this study, latrepirdine was not effective in improv-
ing cognition or global function in individuals withmild
to moderate HD as measured by the MMSE and the
CIBIC-Plus. As in previous studies,4,18,27 latrepirdine was
generally well tolerated, but the results did not confirm
the potential signal of cognitive improvement on the
MMSE observed in the previous HD clinical trial.8
Among the potential explanations for the failure to
demonstrate benefit in this study include an inadequate
dosage of the drug, insufficient duration of treatment, in-
appropriate outcome measures, or a lack of therapeutic
benefit in this population. The dosage of latrepirdine (20
mg 3 times daily) used in this study was the same as in
the previous safety and tolerability study,8 whereas the
duration was twice as long. However, no indication of
benefit was observed at any time point. Despite the pro-
gressive nature of HD, the mean MMSE scores in both
groups improved significantly from baseline during the
6-month study, raising questions about the effects of pla-
cebo in such trials, although such an effect was not seen
in the previous trial.8 The appropriate cognition and global
outcomemeasures for a cognitive clinical trial in HD are
also not established. The MMSE was selected because it
is a well-established cognitive outcome measure in cog-
nition trials in Alzheimer disease and Parkinson dis-
ease.28,29 The MMSE has long been used to assess cogni-
tive deficits in HD17 and demonstrated a potential
beneficial signal in the prior study,8 in contrast to other
cognitive outcomemeasures, including theAlzheimerDis-
ease Assessment Scale–cognitive subscale and cognitive
measures of theUnifiedHuntington’s Disease Rating Scale
(verbal fluency, symbol digit modalities test, and Stroop
color naming,word reading, and interference tests).Other
cognitive outcomemeasures, such as the Montreal Cog-
nitiveAssessment30 or specificmeasures of executive func-
tion or attention, might be more sensitive to changes in
HD and await evaluation in future clinical trials. The
choice of the CIBIC-Plus as a global outcome measure
was more challenging because no sensitive, well-
validated instrument for assessing global function in HD
during the short term exists, although efforts in devel-
oping such an instrument are under way.31 The study re-
sults also advise caution in interpreting efficacy signals
in early-stage trials, especially when multiple outcome
measures are used without a prespecified hierarchy of
analysis or an adjustment for multiple comparisons.
Although the results of this study were disappoint-
ing, the trial lays the foundation for future investiga-
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Figure 2. Change over time in the Mini-Mental State Examination (MMSE)
score by treatment group. Values plotted are adjusted mean changes
from baseline, estimated using a repeated-measures analysis of covariance
model with week, region, treatment group, baseline MMSE score,
tetrabenazine use, and the interaction between week and treatment group.
See the “Statistical Analysis” subsection for details. Bars represent 1 SE
of the mean.
Table 3. Distribution of CIBIC-Plus Response (Co-primary
Outcome Measure) by Treatment Groupa
Response
Latrepirdine Group,
%
(n = 195)
Placebo Group, %
(n = 198)
Marked worsening 0.5 1.0
Moderate worsening 5.6 5.6
Minimal worsening 22.6 20.2
No change 40.0 43.9
Minimal improvement 24.1 23.7
Moderate
improvement
6.2 4.5
Marked improvement 1.0 1.0
Abbreviation: CIBIC-Plus, Clinician Interview–Based Impression
of Change, plus carer interview.
aP = .84 for comparison of treatment groups (stratified
Cochran-Mantel-Haenszel mean score test). See the “Statistical Analysis”
subsection for details.
Table 4. Adverse Events by Treatment Groupa
Event
Latrepirdine
Group, No. (%)
(n = 200)
Placebo Group,
No. (%)
(n = 203)
Fall 30 (15.0) 32 (15.8)
Worsening chorea 16 (8.0) 8 (3.9)
Somnolence 11 (5.5) 14 (6.9)
Headache 11 (5.5) 7 (3.4)
Diarrhea 8 (4.0) 9 (4.4)
Nasopharyngitis 9 (4.5) 8 (3.9)
Dysphagia 8 (4.0) 6 (3.0)
Anxiety 8 (4.0) 6 (3.0)
Depression 8 (4.0) 5 (2.5)
Urinary tract infection 5 (2.5) 7 (3.4)
Dry mouthb 9 (4.5) 2 (1.0)
Vomiting 4 (2.0) 7 (3.4)
Insomnia 4 (2.0) 7 (3.4)
Nausea 3 (1.5) 7 (3.4)
Fatiguec 10 (5.0) 0
Upper respiratory tract infection 4 (2.0) 6 (3.0)
Dizziness 5 (2.5) 5 (2.5)
aAdverse events that occurred in at least 10 participants are reported.
bP = .03, Fisher exact test.
cP ! .001, Fisher exact test.
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tions of HD experimental therapeutics aimed at cogni-
tion. This study was the largest trial by far of any drug
aimed at improving cognition in HD, including 64 cen-
ters in 11 countries across 3 continents, with assess-
ments conducted in different languages.2,32-34 Despite the
potential for heterogeneity, the study results were gen-
erally consistent across all languages and regions. En-
rollment in the study also exceeded expectations, and re-
tention was high, with only 7.4% of participants
withdrawing from the 6-month study.
Translating scientific results in HD and other neuro-
degenerative disorders into efficacious treatments re-
mains a challenge. Advances in our understanding of the
origin and cause of HD, the identification of biomarkers
for the condition,35 and the development of therapies
aimed at the underlying pathogenesis in HD are pro-
gressing.36 These novel findings, coupled with the infra-
structure for clinical investigations, will be needed to as-
sess future treatments aimed at reducing the growing
burden of cognitive impairment fromHDand related neu-
rodegenerative disorders.36,37
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